Vardenafil Hydrochloride Tablet
Product Images NDC 72162-2236

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Vardenafil Hydrochloride (NDC 72162-2236). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622236)

Label for Vardenafil Hydrochloride Tablets 20 mg, oral tablets, containing 30 tablets per container. The label displays the NDC number 72162-2236-3 and includes storage instructions, dosage guideline (one tablet daily), and a warning to keep out of reach of children. The labeler is Bryant Ranch Prepack, with manufacturing by Rivopharm SA.*

FDA Label Image

Chemical Structure (Vardenafil Figure 1)

Chemical structure of Vardenafil Hydrochloride, showing its molecular framework including rings and functional groups, annotated with hydrochloride and water of hydration components.*

FDA Label Image

Figure 1 (Vardenafil Figure 2)

Three line graphs showing mean maximal changes over time for systolic blood pressure, diastolic blood pressure, and heart rate in relation to timing of Vardenafil treatment pre-NTG. The x-axes indicate timing intervals (24h, 8h, 4h, 1h), while the y-axes measure changes in mmHg for blood pressures and bpm for heart rate, each with error bars indicating variability.*

FDA Label Image

Figure 2 (Vardenafil Figure 3)

A line graph showing mean change in mmHg blood pressure over time (hours) for placebo and vardenafil 5 mg under simultaneous and 6-hour separation dosing conditions. The graph compares blood pressure changes from 0 to 6 hours for placebo (circle markers) and vardenafil 5 mg (solid circle and triangle markers) with corresponding legend.*

FDA Label Image

Figure 3 (Vardenafil Figure 4)

A line graph illustrating the mean change in mmHg over time (hours) for placebo and 5 mg Vardenafil under simultaneous and 6-hour separation dosing conditions. The y-axis represents mean change in mmHg, and the x-axis shows time from 0 to 6 hours. Four lines compare placebo and Vardenafil effects under different timing scenarios.*

FDA Label Image

Figure 4 (Vardenafil Figure 5)

A line graph showing mean change in mmHg over time (hours) comparing placebo and vardenafil at 10 mg and 20 mg doses across two stages. The x-axis represents time in hours from 0 to 6, and the y-axis represents mean change in mmHg ranging from -10 to 5. Data points indicate cardiovascular measurements over time for placebo (open circle and triangle lines) and vardenafil (solid circle and triangle lines) groups.*

FDA Label Image

Figure 5 (Vardenafil Figure 6)

A line graph showing mean blood pressure change (mmHg) over time (hours) for Vardenafil tablets at 5 mg and 10 mg doses, compared to placebo stages 1 and 2. The y-axis indicates mean change in mmHg, while the x-axis represents time in hours, depicting fluctuating blood pressure changes across the 6-hour period.*

FDA Label Image

Figure 6 (Vardenafil Figure 7)

A line graph titled 'TERAZOSIN' showing mean change in mmHg over a 6-hour period comparing placebo, 10 mg vardenafil, and 20 mg vardenafil under 6-hour separation and simultaneous conditions. The graph plots mean blood pressure changes over time with multiple markers representing different treatments.*

FDA Label Image

Figure 7 (Vardenafil Figure 8)

Line graph titled 'TAMSULOSIN' showing mean change in mmHg over time (hours) for six treatments: placebo with 6-hour separation, 10 mg Vardenafil with 6-hour separation, 20 mg Vardenafil with 6-hour separation, placebo simultaneous, 10 mg Vardenafil simultaneous, and 20 mg Vardenafil simultaneous. The x-axis represents time from 0 to 6 hours and the y-axis represents mean change in mmHg from 10 to -15.*

FDA Label Image

Figure 8 (Vardenafil Figure 9)

A graph displaying plasma concentration (µg/L) over time (hours) following administration. The plot shows a peak plasma concentration reached within the first few hours, followed by a gradual decline to near zero by 24 hours, with error bars indicating variability at each time point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.